Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Project Summary


The overall aim of our work is to unravel the immunopathogenesis in the early phases of allergic and rheumatic diseases, exclusively in humans. To reach this goal we study prospective cohorts starting before diagnosis, early after diagnosis or during established disease and collect samples from blood, synovial fluid and synovial biopsies. Our work is translational with close collaboration between experimental and clinical researchers. We collect birth cohorts to study allergic disease, early rheumatoid arthritis patient cohorts and systemic lupus erythematosus patient cohorts and investigate clinical, immunological and environmental factors in relation to disease development and outcomes. We also study the effect of different treatments in rheumatoid arthritis and the relation of treatment outcomes and immunological biomarkers.

  • A major recent discovery we have made in the birth cohorts is that increased proportions of circulating transitional/naïve B-cells already at birth predicts allergy development in both infants and children up to 8 years of age. Also, the cytokine BAFF, B-cell activating factor, is found in lower levels at birth in children who develop allergy. Another novel discovery is that human placental stromal cells secrete BAFF in response to interferons, and that children born of mothers exposed to a dairy farm environment during pregnancy have higher BAFF levels in blood at birth.
     
  • With regards to early untreated rheumatoid arthritis we have recently reported that the T cell subtype profile in blood is dominated by Th2 and Th17 cells, which points to their importance in the pathogenesis. Th2 cells have previously been poorly studied in early rheumatoid arthritis. Further, we have shown that the interferon-induced chemokine CXCL10 in blood is related to the degree of disease activity in early rheumatoid arthritis, but none of the T-cells subtypes.

 

Anna Rudin

Kontaktinformation

Anna Rudin

Box 480, 405 30 Göteborg

Besöksadress:
Guldhedsgatan 10A

Telefon:
031-342 46 43

Sidansvarig: kommunikation@medicine.gu.se|Sidan uppdaterades: 2017-06-16
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?